China’s national regulator has approved Sinovac Biotech’s COVID-19 vaccine for use by the general public.
This is the second vaccine approved by China’s National Medical Products Administration (NMPA).
Both of the vaccines, along with another experimental vaccine from Sinopharm, have been used in China’s vaccination programme.
More than 31 million doses have been administered, mainly targeting groups at higher infection risks, while a fourth experimental vaccine from CanSino Biologics has been given to military personnel.
Read the full article.
Refana Inc., is United States registered private corporation dedicated to finding practical and innovative solutions to the world's medical problems. By utilizing a highly collaborative open source system of research and development Refana has been able to attract world leaders in their respective scientific and medical fields to work on these problems. Through this model Refana hopes to greatly accelerate the vaccine development process for Covid-19 and help protect not only the health of the world, but also the economies and stability of nations at risk.